Loading
Life sciences · Journal article
Acta Neuropathologica Communications · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Immunomodulatory therapies have emerged as promising treatments for cancer, where poly(I:C), a synthetic double-stranded RNA, is currently under clinical investigation for its ability to control myeloid cell function and T cell infiltration. While poly(I:C) mimics viral infection and activates Toll-like receptor 3 (TLR3), its exact mechanism of action in cancer is unknown. Our survey of multiple human tumors demonstrated that TLR3 is enriched in gliomas, particularly low-grade gliomas (LGGs; pilocytic astrocytoma, PA) in individuals with the neurofibromatosis type 1 (NF1) cancer predisposition syndrome. Using two independently generated murine models of NF1-LGG (optic pathway glioma, OPG), we evaluated the efficacy of poly(I:C) and examined tumor-associated myeloid cell (TAM) function, chemokine expression, and signaling pathway activation in vivo and in vitro. We found that poly(I:C) durably suppressed tumor growth in these two Nf1 -OPG strains, with sustained glioma suppression and normalized retinal nerve fiber thickness 16 weeks following treatment cessation in vivo. Importantly, poly(I:C) induced TAM Ccl3 production through both TLR3 and MDA5-dependent pathways to control Ccl3-mediated intratumoral CD8 + T cell trafficking. Since we found that Ccl3 is enriched in microglia from both human PA and mouse Nf1 -OPG TAM, we used fresh murine Nf1 +/− microglia to demonstrate that these independent pathways activated distinct intracellular cascades in vitro, including TLR3/MEK and MDA5/NFκB signaling, which both converge on ERK activation. Collectively, these findings identify the innate immune mechanisms by which poly(I:C) regulates TAM-mediated T cell infiltration and LGG growth, highlighting the critical role of innate immune sensors in regulating non-neoplastic cells within the brain tumor microenvironment.